Alnylam Pharmaceuticals, Inc. (ALNY) Shares Bought by Wells Fargo & Company MN

Wells Fargo & Company MN lifted its position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 1.6% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 199,949 shares of the biopharmaceutical company’s stock after acquiring an additional 3,146 shares during the period. Wells Fargo & Company MN’s holdings in Alnylam Pharmaceuticals were worth $17,499,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors have also recently modified their holdings of the company. Principal Financial Group Inc. grew its position in Alnylam Pharmaceuticals by 5.4% during the first quarter. Principal Financial Group Inc. now owns 24,525 shares of the biopharmaceutical company’s stock valued at $2,921,000 after buying an additional 1,263 shares during the period. BNP Paribas Arbitrage SA grew its position in Alnylam Pharmaceuticals by 18.7% during the second quarter. BNP Paribas Arbitrage SA now owns 18,244 shares of the biopharmaceutical company’s stock valued at $1,797,000 after buying an additional 2,870 shares during the period. Sumitomo Mitsui Asset Management Company LTD grew its position in Alnylam Pharmaceuticals by 249.8% during the second quarter. Sumitomo Mitsui Asset Management Company LTD now owns 19,432 shares of the biopharmaceutical company’s stock valued at $1,913,000 after buying an additional 13,877 shares during the period. Sumitomo Mitsui Trust Holdings Inc. boosted its position in Alnylam Pharmaceuticals by 6.3% during the second quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 271,295 shares of the biopharmaceutical company’s stock worth $26,720,000 after purchasing an additional 16,110 shares during the period. Finally, First Trust Advisors LP boosted its position in Alnylam Pharmaceuticals by 22.9% during the second quarter. First Trust Advisors LP now owns 659,766 shares of the biopharmaceutical company’s stock worth $64,980,000 after purchasing an additional 123,099 shares during the period. 88.46% of the stock is currently owned by hedge funds and other institutional investors.

A number of brokerages have weighed in on ALNY. Stifel Nicolaus upgraded shares of Alnylam Pharmaceuticals from a “hold” rating to a “buy” rating and increased their target price for the stock from $95.00 to $125.00 in a research report on Monday, August 6th. Leerink Swann began coverage on shares of Alnylam Pharmaceuticals in a research report on Tuesday, November 27th. They set a “market perform” rating and a $63.00 target price for the company. Needham & Company LLC reiterated a “buy” rating and set a $152.00 target price on shares of Alnylam Pharmaceuticals in a research report on Monday, August 13th. Jefferies Financial Group reiterated a “buy” rating and set a $149.00 target price on shares of Alnylam Pharmaceuticals in a research report on Monday, August 6th. Finally, ValuEngine lowered shares of Alnylam Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, August 7th. Three analysts have rated the stock with a sell rating, two have given a hold rating and thirteen have given a buy rating to the stock. The company has a consensus rating of “Buy” and an average price target of $138.44.

ALNY stock opened at $84.29 on Tuesday. The company has a debt-to-equity ratio of 0.02, a current ratio of 11.05 and a quick ratio of 10.96. Alnylam Pharmaceuticals, Inc. has a 12 month low of $63.57 and a 12 month high of $153.99. The company has a market capitalization of $8.20 billion, a PE ratio of -15.55 and a beta of 2.54.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last released its quarterly earnings data on Wednesday, November 7th. The biopharmaceutical company reported ($2.43) EPS for the quarter, missing analysts’ consensus estimates of ($2.02) by ($0.41). Alnylam Pharmaceuticals had a negative net margin of 754.13% and a negative return on equity of 43.07%. The firm had revenue of $2.07 million during the quarter, compared to the consensus estimate of $22.66 million. During the same quarter last year, the business posted ($1.34) earnings per share. Alnylam Pharmaceuticals’s revenue was down 87.9% compared to the same quarter last year. Equities research analysts predict that Alnylam Pharmaceuticals, Inc. will post -7.62 EPS for the current year.

TRADEMARK VIOLATION WARNING: This piece of content was first published by Community Financial News and is owned by of Community Financial News. If you are viewing this piece of content on another site, it was stolen and reposted in violation of US and international copyright law. The original version of this piece of content can be viewed at https://www.com-unik.info/2018/12/04/alnylam-pharmaceuticals-inc-alny-shares-bought-by-wells-fargo-company-mn.html.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, discovers, develops, and commercializes novel therapeutics based on RNA interference (RNAi). Its pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, and hepatic infectious diseases. The company's clinical development programs include Patisiran, which is in Phase III clinical trial for the treatment of hereditary transthyretin-mediated amyloidosis; Givosiran that is in Phase III trial to treat acute hepatic porphyrias; Fitusiran, an investigational RNAi therapeutic that is in Phase II open-label extension and Phase III clinical trial for the treatment of hemophilia and rare bleeding disorders; and Inclisiran, which is in III clinical trial for hypercholesterolemia.

Recommended Story: What is the NASDAQ Stock Market?

Want to see what other hedge funds are holding ALNY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY).

Institutional Ownership by Quarter for Alnylam Pharmaceuticals (NASDAQ:ALNY)

Receive News & Ratings for Alnylam Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit